2024 | Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes | Rastogi, Priya; O'Shaughnessy, Joyce; Martin, Miguel; Boyle, Frances; Cortes, Javier; Rugo, Hope S; Goetz, Matthew P; Hamilton, Erika P; CHIUN-SHENG HUANG ; et al., | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 3 | | |